Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

1.800 -0.020 (-1.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inovio Pharmaceuticals, Inc. - Common Stock

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
From Inovio Pharmaceuticals, Inc.
Via GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Does Amarin Deserve a Spot in Your Portfolio after Earnings ?
Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio. 
Via MarketBeat
Topics Earnings
Exposures Financial
Growing Acceptance Of Digital Health Services is a Huge Boon for Healthcare Cloud Computing Market
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Cloud computing increases real-time data collection and improves accessibility to the data. It has outpaced the conventional... 
Via FinancialNewsMedia
Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the... 
Via FinancialNewsMedia
Exposures COVID-19
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing... 
Via FinancialNewsMedia
Exposures COVID-19
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in... 
Via FinancialNewsMedia
Exposures COVID-19
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
Exposures COVID-19
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
From Kahn Swick & Foti, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.